Ischaemic cardiovascular risk and prescription of non-steroidal anti-inflammatory drugs for musculoskeletal complaints

References

• Airaksinen O, Brox JI, Cedraschi C, Hildebrandt J, Klaber-Moffett J, Kovacs F, et al. Chapter 4. European guidelines for the management of chronic nonspecific low back pain. Eur Spine J. 2006;15:S192–300.
   Google Scholar
• Chavannes AW, Mens JMA, Koes BW, Lubbers WJ, Ostelo R, Spinnewijn WEM, et al. NHG-standaard aspecifieke lagerugpijn [NHG guideline non-specific low back pain]. Huisarts Wet. 2005;48:113–23.
   Google Scholar
• McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Jan 24 [Epub ahead of print].
   Google Scholar
• Van Tulder M, Becker A, Bekkering T, Breen A, del Real MT, Hutchinson A, et al. Chapter 3. European guidelines for the management of acute nonspecific low back pain in primary care. Eur Spine J. 2006;15:S169–91.
   Google Scholar
• Winters JC, Van der Windt DAWM, Spinnewijn WEM, De Jongh AC, Van der Heijden GJMG, Buis PAJ, et al. NHG-standaard schouderklachten [NHG guideline shoulder complaints]. Huisarts Wet. 2008;51:555–65.
   Google Scholar
• Zhang W, Doherty M, Leeb BF, Alekseeva L, Arden NK, Bijlsma JW, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:377–88.
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs: A meta-analysis. Ann Intern Med. 1991;115:787–96.
   PubMed Web of Science ®Google Scholar
• Hernandez-Diaz S, Rodriguez LA. Association between non-steroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: An overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160:2093–99.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520–28.
   PubMed Web of Science ®Google Scholar
• Rostom A, Muir K, Dube C, Jolicoeur E, Boucher M, Joyce J, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: A Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol. 2007;5:818–28.
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomised controlled trial. Lancet. 2004;364:665–74.
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247–55.
   Google Scholar
• Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–1102.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Press release: European Medicines Agency concludes action on COX-2 inhibitors. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/01/WC500059088.pdf (accessed 21 Nov 2013).
   Google Scholar
• Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis?Meta-analysis of randomised trials. BMJ. 2006;332:1302–8.
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and non-selective inhibitors of cyclooxygenase 2. JAMA. 2006;296:1633–44.
   PubMed Web of Science ®Google Scholar
• Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: Network meta- analysis. BMJ. 2011;342:c7086.
   PubMed Web of Science ®Google Scholar
• Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Pariente A, Scotti L, et al. Stroke risk and NSAIDs: A systematic review of observational studies. Pharmacoepidemiol Drug Saf. 2011;20:1225–36.
   PubMed Web of Science ®Google Scholar
• Chan FK, Abraham NS, Scheiman JM, Laine L. Management of patients on non-steroidal anti-inflammatory drugs: A clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Non-steroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol. 2008;103:2908–18.
   PubMed Web of Science ®Google Scholar
• Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104:728–38.
   PubMed Web of Science ®Google Scholar
• Warlé-Van Herwaarden MF, Kramers C, Sturkenboom MC, Van den Bemt PMLA, De Smet PAGM. Targeting outpatient drug safety: Recommendations of the Dutch Harm- Wrestling Task Force. Drug Saf. 2012;35:245–59.
   PubMed Web of Science ®Google Scholar
• Van der Lei J, Duisterhout JS, Westerhof HP, van der Does E, Cromme PV, Boon WM. The introduction of computer-based patient records in The Netherlands. Ann Intern Med. 1993; 119:1036–41.
   PubMed Web of Science ®Google Scholar
• Vlug AE, van der Lei J, Mosseveld BM, van Wijk MA, van der Linden PD, Sturkenboom MC, et al. Postmarketing surveillance based on electronic patient records: The IPCI project. Methods Inf Med. 1999;38:339–44.
   PubMed Web of Science ®Google Scholar
• Lamberts H WM, Hofmans-Okkens IM. International primary care classifications: The effect of fifteen years of evolution. Fam Pract. 1992;9:330–39.
   PubMed Web of Science ®Google Scholar
• Richtlijn NSAID-gebruik en preventive van maagschade [Guideline NSAID use and prevention of gastric damage]. Utrecht: Dutch Institute for Health Care improvement CBO; 2003.
   Google Scholar
• De Grauw WJC, Kaasjager HAH, Bilo HJG, Faber EF, Flikweer S, Gaillard CAJM, et al. Landelijke transmurale afspraak chronische nierschade [National transmural consensus chronic kidney disease]. Huisarts Wet. 2009;52:586–97.
   Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. Available at: http://www.whocc.no/ (accessed 21 Nov 2013).
   Google Scholar
• McGettigan P, Henry D. Cardiovascular risk with non- steroidal anti-inflammatory drugs: Systematic review of population-based controlled observational studies. PLoS Med. 2011;8:e1001098.
   PubMed Web of Science ®Google Scholar
• Singh BK, Haque SE, Pillai KK. Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity. Expert Opin Drug Metab Toxicol. 2014;10:143–56.
   PubMed Web of Science ®Google Scholar
• Bevolking; kerncijfers [Population; key statistics]. Central Bureau of Statistics; 2012. Available at: http://statline. cbs.nl/StatWeb/publication/?VW = T&DM = SLNL&PA = 37296ned&D1=a&D2=0,10,20,30,40,50,(l-1)-l &HD = 130215-1329&HDR = G1&STB = T (accessed 3 March 2014).
   Google Scholar
• Brattwall M, Turan I, Jakobsson J. Musculoskeletal pain: Prescription of NSAID and weak opioid by primary health care physicians in Sweden 2004–2008: A retrospective patient record review. J Pain Res. 2010;3:131–5.
   PubMedGoogle Scholar
• Bedson J, Belcher J, Martino OI, Ndlovu M, Rathod T, Walters K, et al. The effectiveness of national guidance in changing analgesic prescribing in primary care from 2002 to 2009: An observational database study. Eur J Pain. 2013; 17:434–43.
   PubMed Web of Science ®Google Scholar
• Alacqua M, Trifiro G, Cavagna L, Caporali R, Montecucco CM, Moretti S, et al. Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: The effect of rofecoxib withdrawal. Arthritis Rheum. 2008;59:568–74.
   PubMedGoogle Scholar
• Valkhoff VE, van Soest EM, Masclee GM, de Bie S, Mazzaglia G, Molokhia M, et al. Prescription of nonselective NSAIDs, coxibs and gastroprotective agents in the era of rofecoxib withdrawal: A 617 400-patient study. Aliment Pharmacol Ther. 2012;36:790–9.
   PubMed Web of Science ®Google Scholar
• Mosis G, Stijnen T, Castellsague J, Dieleman JP, van der Lei J, Stricker BH, et al. Channeling and prevalence of cardiovascular contraindications in users of cyclooxygenase 2 selective non-steroidal antiinflammatory drugs. Arthritis Rheum. 2006;55:537–42.
   PubMed Web of Science ®Google Scholar
• Usher C, Bennett K, Teeling M, Feely J. Characterizing new users of NSAIDs before and after rofecoxib withdrawal. Br J Clin Pharmacol. 2006;63:494–97.
   PubMed Web of Science ®Google Scholar
• Theibaud P, Patel BV, Nichol MB. Impact of rofecoxib withdrawal on cyclooxygenase-2 utilization among patients with and without cardiovascular risk. Value Health. 2006; 9:361–8.
   PubMed Web of Science ®Google Scholar